Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

February 20, 2020

Conditions

Healthy VolunteershATTR Amyloidosis

Interventions

DRUG

ION-682884

ION-682884 administered SC

DRUG

Placebo

Placebo comparator calculated volume to match ION-682884 administered SC

DIETARY_SUPPLEMENT

Vitamin A

Oral supplement

Trial Locations (1)

Bio Pharma Services, Inc., Toronto